Eli Lilly (LLY) is in advanced talks to acquire Ventyx Biosciences (VTYX) for more than USD 1bln, according to WSJ citing sources

Eli Lilly's potential acquisition of Ventyx Biosciences for over $1 billion marks a significant move in the pharmaceuticals sector, suggesting their strategy may be focused on expanding their biotechnology portfolio.

Newsquawk StaffNewswiresPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

US FX WRAP: The Dollar inches higher as the Aussie continues to benefit from surging metals

TREASURY WRAP: T-NOTE FUTURES (H6) SETTLE 3 TICKS LOWER AT 112-10+

Eli Lilly (LLY) is in advanced talks to acquire Ventyx Biosciences (VTYX) for more than USD 1bln, according to WSJ citing sources

Senior US official says the issue of US acquisition of Greenland is "not going away", and Trump is eager for a deal despite objections from NATO leaders

Senate approves Trump’s White House drug czar pick who supports medical marijuana as rescheduling looms, Marijuana Moment reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal could create ripple effects across the industry, potentially driving M&A activity as peers react to Lilly's consolidation efforts and the strategic rationale behind the purchase.

Related headlines

The whole workspace, free to try.

Try it free